drugset / Trial / NCT02223871
Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects
NaSingle-groupOpen-labelOther
Summary
This was a single-center study using induced blood stage malaria infection to characterize the activity of ACT-451840 against early Plasmodium falciparum blood stage infection
Timeline
- Start
- 2014-06
- Primary completion
- 2014-07
- Completion
- 2014-07
Publications
- Background Marquart L, Baker M, O'Rourke P, McCarthy JS. Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR. Antimicrob Agents Chemother. 2015 Jul;59(7):4249-59. doi: 10.1128/AAC.04942-14. Epub 2015 May 11.
- Results Krause A, Dingemanse J, Mathis A, Marquart L, Mohrle JJ, McCarthy JS. Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects. Br J Clin Pharmacol. 2016 Aug;82(2):412-21. doi: 10.1111/bcp.12962. Epub 2016 May 11.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACT-451840 | Small molecule | 500 mg | Oral |
| Background | Artemether | Small molecule | 20 mg | Oral |
| Background | Primaquine | Small molecule | 45 mg | Oral |
| Background | lumefantrine | Small molecule | 120 mg | Oral |
Indications
No indication recorded.